-

LivaNova Elects Peter Wilver to Board of Directors

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced Peter Wilver has been elected to the Board of Directors, effective immediately. His election was part of the LivaNova 2022 Annual General Meeting of Shareholders (AGM) held on June 13.

Wilver joins the LivaNova Board with more than 30 years of business experience. He retired from Thermo Fisher Scientific, Inc., a provider of laboratory products and services, in 2017 after serving as the company’s Executive Vice President and Chief Administrative Officer since 2015, as well as Senior Vice President and Chief Financial Officer from 2006-2015. He served as Thermo Electron’s Vice President and Chief Financial Officer from 2004-2006, having previously been Vice President, Financial Operations from 2000-2004. Throughout his career, he held financial leadership roles at Honeywell International, Grimes Aerospace Company and General Electric Company. Other public company directorships in the past five years include Evoqua Water Technologies Corporation (current), Shoals Technology Group (current), CIRCOR International, Inc. and Tenet Healthcare Corporation.

“Pete offers a wealth of strategic planning, business development and financial experience with large, multinational manufacturing companies that will bring additional acumen to our accomplished Board of Directors,” said William Kozy, LivaNova Board Chair. “The Board welcomes Pete and looks forward to his engagement and contributions.”

Wilver joins eight other professionals who were re-elected to their Board seats.

About LivaNova

LivaNova PLC is a global medical technology and innovation company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through innovative medical technologies, delivering life-changing improvements for both the Head and Heart. Headquartered in London, LivaNova employs approximately 3,000 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals and healthcare systems worldwide. For more information, please visit www.livanova.com.

Safe Harbor Statement

This news release contains “forward-looking statements” concerning the Company’s goals, beliefs, expectations, strategies, objectives, plans and underlying assumptions and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding changes to the Company’s Board of Directors. Actual events may differ materially from those indicated in forward-looking statements as a result of various factors, including those factors set forth in Item 1A of the Company’s most recent Annual Report on Form 10-K, as supplemented by any risk factors contained in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. LivaNova undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

Contacts

LivaNova Investor Relations and Media Contacts
+1 281-895-2382
Lindsey Little
Senior Director, Investor Relations
InvestorRelations@livanova.com
Deanna Wilke
VP, Corporate Communications
Corporate.Communications@livanova.com

LivaNova PLC

NASDAQ:LIVN
Details
Headquarters: London, United Kingdom
CEO: Vladimir Makatsaria
Employees: 3000
Organization: PUB
Revenues: $1.25B (2024)
Net Income: $63.2M (2024)

Release Summary
LivaNova PLC today announced Peter Wilver has been elected to the Board of Directors, effective immediately.
Release Versions

Contacts

LivaNova Investor Relations and Media Contacts
+1 281-895-2382
Lindsey Little
Senior Director, Investor Relations
InvestorRelations@livanova.com
Deanna Wilke
VP, Corporate Communications
Corporate.Communications@livanova.com

More News From LivaNova PLC

LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual Meeting

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present eight posters at the American Epilepsy Society (AES) Annual Meeting, taking place Dec. 5-9 in Atlanta. These presentations highlight real-world evidence from the CORE-VNS study, the largest prospective, multinational observational study of VNS Therapy™ for Drug-Resistant Epilepsy (DRE), and new health economics analyses. “At the heart of LivaNova’s purpose as a Comp...

LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced Lucile Blaise has joined the Company as Global Head of Commercialization, Obstructive Sleep Apnea (OSA), effective December 1. Blaise reports to Vladimir Makatsaria, Chief Executive Officer and is a member of the Executive Leadership Team. “Lucile is an accomplished healthcare executive with more than 25 years of leadership in the medtech sector,” Makatsaria said. “With her extensive OSA...

LivaNova to Present at Piper Sandler Healthcare Conference in December

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Alex Shvartsburg, Chief Financial Officer, will present a general business update during a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York City. The presentation will take place on Tues., Dec. 2, at 1:30 p.m. Eastern Standard Time. The discussion will be available to all interested parties who register to attend the webcast, which is accessible...
Back to Newsroom